Search

Your search keyword '"Zhai Qiongli"' showing total 137 results
Start Over Author "Zhai Qiongli"
137 results on '"Zhai Qiongli"'

1. Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis

Author

Shen Zongyi, Yin Liqi, Chang Manxia, Wang Haifeng, Hao Mingxuan, Liang Youfeng, Guo Rui, Bi Ying, Wang Jiansong, Yu Changyuan, Li Jinmei, Zhai Qiongli, Cheng Runfen, Zhang Jinku, Sun Jirui, and Yang Zhao

Subjects
lung cancer, medicarpin, cell apoptosis, cell cycle arrest, Pharmaceutical industry, HD9665-9675
Abstract

Lung cancer (LC) is the leading cause of cancer deaths worldwide. Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. However, drug resistance and meta-stasis are two major challenges in cancer therapies. Medicarpin (MED) is an isoflavone compound isolated from alfalfa, which is usually used in traditional medicine. This study was de sig ned to evaluate the anti-LC effect and reveal the underlying mechanisms of MED in vivo and in vitro. We found that MED could significantly inhibit proliferation, induce apoptosis, and cell cycle arrest of A549 and H157 cell lines. Basically, MED induced cell apoptosis of LC cells by upregu lating the expression of pro-apoptotic proteins BAX and Bak1, leading to the cleavage of caspase-3 (Casp3). Moreover, MED inhibited the proliferation of LC cells via downregulating the expression of proliferative protein Bid. Overall, MED inhibited LC cell growth in vitro and in vivo via suppressing cell proliferation and inducing cell apoptosis, suggesting the therapeutic potential of MED in treating LC.

Published
2024
Full Text
View/download PDF

2. Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells

Author

Chen Yuan, Yin Liqi, Hao Mingxuan, Xu Wenkai, Gao Jixian, Sun Yuxin, Wang Qiao, Chen Shi, Liang Youfeng, Guo Rui, Zhang Jinku, Li Jinmei, Zhai Qiongli, Cheng Runfen, Wang Jiansong, Wang Haifeng, and Yang Zhao

Subjects
bladder cancer, medicarpin, cell cycle, arrest, apoptosis, therapy, Pharmaceutical industry, HD9665-9675
Abstract

Bladder cancer (BC) is the tenth most commonly diagnosed cancer. High recurrence, chemoresistance, and low response rate hinder the effective treatment of BC. Hence, a novel therapeutic strategy in the clinical management of BC is urgently needed. Medicarpin (MED), an isoflavone from Dalbergia odorifera, can promote bone mass gain and kill tumor cells, but its anti-BC effect remains obscure. This study reve aled that MED effectively inhibited the proliferation and arrested the cell cycle at the G1 phase of BC cell lines T24 and EJ-1 in vitro. In addition, MED could significantly suppress the tumor growth of BC cells in vivo. Mechanically, MED induced cell apoptosis by upregulating pro-apoptotic proteins BAK1, Bcl2-L-11, and caspase-3. Our data suggest that MED suppresses BC cell growth in vitro and in vivo via regulating mitochondria-mediated intrinsic apoptotic pathways, which can serve as a promising candidate for BC therapy.

Published
2023
Full Text
View/download PDF

8. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma

Author

Yi, Shuhua, primary, Yan, Yuting, additional, Jin, Meiling, additional, Bhattacharya, Supriyo, additional, Wang, Yi, additional, Wu, Yiming, additional, Yang, Lu, additional, Gine, Eva, additional, Clot, Guillem, additional, Chen, Lu, additional, Yu, Ying, additional, Zou, Dehui, additional, Wang, Jun, additional, Phan, An T., additional, Cui, Rui, additional, Li, Fei, additional, Sun, Qi, additional, Zhai, Qiongli, additional, Wang, Tingyu, additional, Yu, Zhen, additional, Liu, Lanting, additional, Liu, Wei, additional, Lyv, Rui, additional, Sui, Weiwei, additional, Huang, Wenyang, additional, Xiong, Wenjie, additional, Wang, Huijun, additional, Li, Chengwen, additional, Xiao, Zhijian, additional, Hao, Mu, additional, Wang, Jianxiang, additional, Cheng, Tao, additional, Bea, Silvia, additional, Herrera, Alex F., additional, Danilov, Alexey, additional, Campo, Elias, additional, Ngo, Vu N., additional, Qiu, Lugui, additional, and Wang, Lili, additional

Published
2024
Full Text
View/download PDF

9. Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis

Author

SHEN, ZONGYI, YIN, LIQI, CHANG, MANXIA, WANG, HAIFENG, HAO, MINGXUAN, LIANG, YOUFENG, GUO, RUI, BI, YING, WANG, JIANSONG, YU, CHANGYUAN, LI, JINMEI, ZHAI, QIONGLI, CHENG, RUNFEN, ZHANG, JINKU, SUN, JIRUI, YANG, ZHAO, SHEN, ZONGYI, YIN, LIQI, CHANG, MANXIA, WANG, HAIFENG, HAO, MINGXUAN, LIANG, YOUFENG, GUO, RUI, BI, YING, WANG, JIANSONG, YU, CHANGYUAN, LI, JINMEI, ZHAI, QIONGLI, CHENG, RUNFEN, ZHANG, JINKU, SUN, JIRUI, and YANG, ZHAO

Abstract

Lung cancer (LC) is the leading cause of cancer deaths worldwide. Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. However, drug resistance and metastasis are two major challenges in cancer therapies. Medicarpin (MED) is an isoflavone compound isolated from alfalfa, which is usually used in traditional medicine. This study was designed to evaluate the anti-LC effect and reveal the underlying mechanisms of MED in vivo and in vitro. We found that MED could significantly inhibit proliferation, induce apoptosis, and cell cycle arrest of A549 and H157 cell lines. Basically, MED induced cell apoptosis of LC cells by upregulating the expression of pro-apoptotic proteins BAX and Bak1, leading to the cleavage of caspase-3 (Casp3). Moreover, MED inhibited the proliferation of LC cells via downregulating the expression of proliferative protein Bid. Overall, MED inhibited LC cell growth in vitro and in vivo via suppressing cell proliferation and inducing cell apoptosis, suggesting the therapeutic potential of MED in treating LC.

Published
2024

10. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Au, Wing-Yan, Chiu, Brian, Fan, Lei, Li, Zheng, LAM, Tai Hing, Liang, Raymond, Yeh, Su-Peng, Xu, Jun, Ip, Dennis Kai Ming, Li, Gandi, Xu, Gang, Wang, Xiaodong, Bai, Ou, Cai, Qing-Qing, Xia, Yi, Chen, Jie-Rong, Luo, Chun-Ling, Xiong, Xiang-Yu, Zeng, Yanni, Wei, Pan-Pan, Liu, Chu-Jun, Liu, Yu-Xiang, Cao, Yu-Lu, He, Shuai, Liu, Yang, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Kee, Rebecca Xiangpin, Tan, Jing, Liu, Yanhui, Zhang, Fen, Feng, Yanfen, Rao, Huilan, Chng, Wee Joo, Chan, Jason Yong Sheng, Somasundaram, Nagavalli D/O, Tao, Miriam, Ras, Mohamad Farid Bin Harunal, Yeoh, Kheng-Wei, Goh, Yeow Tee, Ong, Shin Yeu, Grigoropoulos, Nicholas Francis, Wong, Esther Kam Yin, Pang, Jane Wan Lu, Lim, Jing Quan, Chia, Burton Kuan Hui, Kim, Seok Jin, Yoon, Sang Eun, Choi, Seungkyu, Kuo, Ching-Yuan, Chen, Tsai-Yun, Su, Yu-Chieh, Huang, Wen-Tsung, Lee, Ming-Yang, Yao, Wenxiu, Ngan, Kai-Cheong, Liu, Herman, Lee, Harold, Yip, Sze-Fai, Liu, Jie, Li, Jianyong, Rabkin, Charles S., Berndt, Sonja, Bassig, Bryan, Hu, Wei, Zhao, Mingfeng, Li, Yuming, Zhai, Qiongli, Shao, Zonghong, Qiu, Lugui, Wang, Jianxiang, Xu, Fu-Ping, Chen, Ling, Hou, Yu, Xu, Shuangnian, Huang, Zhen, Xie, Mingling, Li, Ming, Zhong, Shilong, Zhang, Yan, Gu, Dongqing, Wang, Xin, Foo, Jia Nee, Li, Zhiqiang, Dai, Juncheng, Sun, Liangdan, Wang, Zhenzhen, Liu, Hong, Zhou, Hui, Sun, Yonghu, Koh, Woon-Puay, Heng, Chew-Kiat, Hong, Chew Soo, Ahn, Jeeyun, Park, Kyu Hyung, Tin, Aung, Gu, Jieruo, Xia, Xiaojun, Li, Bo, Yu, Xueqing, Lin, Guo-Wang, Xu, Caigang, Chen, Kexin, Huang, Hui-Qiang, Chen, Jieping, Song, Bao, Chan, John K C, Li, Wenyu, Liu, Weiping, Shih, Lee-Yung, Chuang, Wen-Yu, Kim, Won Seog, Tan, Wen, Peng, Rou-Jun, Laurensia, Yurike, Cheah, Daryl Ming Zhe, Huang, DaChuan, Cheng, Chee Leong, Su, Yi-Jiun, Tan, Soo-Yong, Ng, Siok-Bian, Tang, Tiffany Pooi Ling, Han, Kyudong, Wang, Vivien Ya-Fan, Jia, Wei-Hua, Pei, Zhong, Li, Ya-Jun, Gao, Song, Shi, Yongyong, Hu, Zhibin, Zhang, Furen, Zhang, Ben, Zeng, Yi-Xin, Shen, Hongbing, He, Lin, Ong, Choon Kiat, Lim, Soon Thye, Chanock, Stephen, Kwong, Yok-Lam, Lin, Dongxin, Rothman, Nathaniel, Khor, Chiea Chuen, Lan, Qing, and Bei, Jin-Xin

Published
2020
Full Text
View/download PDF

11. RGS1 targeted by miR-191-3p inhibited the stemness properties of esophageal cancer cells by suppressing CXCR4/PI3K/AKT signaling

Author

Xun, Jing, primary, Ma, Yuan, additional, Wang, Botao, additional, Lv, Zongjing, additional, Jiang, Xiaolin, additional, Liu, Bin, additional, Zhang, Lanqiu, additional, Yang, Lei, additional, Yu, Xiangyang, additional, Zhang, Aimin, additional, Gao, Ruifang, additional, Zhai, Qiongli, additional, Cheng, Runfen, additional, Wang, Ximo, additional, Wu, Xueliang, additional, Wu, Yu, additional, and Zhang, Qi, additional

Published
2023
Full Text
View/download PDF

13. Medicarpin suppresses lung cancer cell growth in vitro and in vivoby inducing cell apoptosis

Author

Shen, Zongyi, Yin, Liqi, Chang, Manxia, Wang, Haifeng, Hao, Mingxuan, Liang, Youfeng, Guo, Rui, Bi, Ying, Wang, Jiansong, Yu, Changyuan, Li, Jinmei, Zhai, Qiongli, Cheng, Runfen, Zhang, Jinku, Sun, Jirui, and Yang, Zhao

Abstract

Lung cancer (LC) is the leading cause of cancer deaths worldwide. Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. However, drug resistance and meta-stasis are two major challenges in cancer therapies. Medicarpin (MED) is an isoflavone compound isolated from alfalfa, which is usually used in traditional medicine. This study was de sig ned to evaluate the anti-LC effect and reveal the underlying mechanisms of MED in vivoand in vitro. We found that MED could significantly inhibit proliferation, induce apoptosis, and cell cycle arrest of A549 and H157 cell lines. Basically, MED induced cell apoptosis of LC cells by upregu lating the expression of pro-apoptotic proteins BAX and Bak1, leading to the cleavage of caspase-3 (Casp3). Moreover, MED inhibited the proliferation of LC cells viadownregulating the expression of proliferative protein Bid. Overall, MED inhibited LC cell growth in vitroand in vivo viasuppressing cell proliferation and inducing cell apoptosis, suggesting the therapeutic potential of MED in treating LC.

Published
2024
Full Text
View/download PDF

14. Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells

Author

CHEN, YUAN, YIN, LIQI, HAO, MINGXUAN, XU, WENKAI, GAO, JIXIAN, SUN, YUXIN, WANG, QIAO, CHEN, SHI, LIANG, YOUFENG, GUO, RUI, ZHANG, JINKU, LI, JINMEI, ZHAI, QIONGLI, CHENG, RUNFEN, WANG, JIANSONG, WANG, HAIFENG, YANG, ZHAO, CHEN, YUAN, YIN, LIQI, HAO, MINGXUAN, XU, WENKAI, GAO, JIXIAN, SUN, YUXIN, WANG, QIAO, CHEN, SHI, LIANG, YOUFENG, GUO, RUI, ZHANG, JINKU, LI, JINMEI, ZHAI, QIONGLI, CHENG, RUNFEN, WANG, JIANSONG, WANG, HAIFENG, and YANG, ZHAO

Abstract

Bladder cancer (BC) is the tenth most commonly diagnosed cancer. High recurrence, chemoresistance, and low response rate hinder the effective treatment of BC. Hence, a novel therapeutic strategy in the clinical management of BC is urgently needed. Medicarpin (MED), an isoflavone from Dalbergia odorifera, can promote bone mass gain and kill tumor cells, but its anti-BC effect remains obscure. This study revealed that MED effectively inhibited the proliferation and arrested the cell cycle at the G1 phase of BC cell lines T24 and EJ-1 in vitro. In addition, MED could significantly suppress the tumor growth of BC cells in vivo. Mechanically, MED induced cell apoptosis by upregulating pro-apoptotic proteins BAK1, Bcl2-L-11, and caspase-3. Our data suggest that MED suppresses BC cell growth in vitro and in vivo via regulating mitochondria-mediated intrinsic apoptotic pathways, which can serve as a promising candidate for BC therapy.

Published
2023

16. Combinatorial Application of Papain and CD66B for Isolating Glioma-Associated Neutrophils

Author

Li, Wenliang, primary, Jin, Xun, primary, Xu, Xing, additional, Yang, Yongchang, additional, Liu, Yancheng, additional, Ge, Xianglian, additional, Yi, Tailong, additional, Xie, Yang, additional, Ning, Chunlan, additional, Shen, Shengfu, additional, Sun, Zengfeng, additional, Zhang, Zhen, additional, Zhai, Qiongli, additional, Wang, Xiaoguang, additional, Meng, Xianghui, additional, Dong, Jun, additional, Huang, Qiang, additional, and Yang, Xuejun, additional

Published
2022
Full Text
View/download PDF

17. Glabridin inhibits urothelial bladder carcinoma cell growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest

Author

Yang, Zhao, primary, Bi, Ying, additional, Xu, Wenkai, additional, Guo, Rui, additional, Hao, Mingxuan, additional, Liang, Youfeng, additional, Shen, Zongyi, additional, Yin, Liqi, additional, Yu, Changyuan, additional, Wang, Shihui, additional, Wang, Jiansong, additional, Li, Jinmei, additional, Zhang, Jinku, additional, Cheng, Runfen, additional, Zhai, Qiongli, additional, and Wang, Haifeng, additional

Published
2022
Full Text
View/download PDF

19. Glabridin inhibits urothelial bladder carcinoma cell growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest.

Author

Yang, Zhao, Bi, Ying, Xu, Wenkai, Guo, Rui, Hao, Mingxuan, Liang, Youfeng, Shen, Zongyi, Yin, Liqi, Yu, Changyuan, Wang, Shihui, Wang, Jiansong, Li, Jinmei, Zhang, Jinku, Cheng, Runfen, Zhai, Qiongli, and Wang, Haifeng

Subjects
TRANSITIONAL cell carcinoma, CELL growth, CELL cycle, APOPTOSIS, ARREST, GENE expression
Abstract

Glabridin (GLA) has a variety of biological activities and therapeutic effects in cancers. Whereas the effect of GLA on urothelial bladder carcinoma (UBC) cells and its underlying mechanisms remain unknown. The study revealed the effect of GLA on UBC and the potential mechanism of inducing cell apoptosis in vivo and in vitro. After treated with different concentrations of GLA, the cell activity decreased in a time‐ and dose‐dependent manner. The IC50 values of BIU‐87 and EJ cells at 48 h were 6.02 μg/ml (18.6 μm) and 4.36 μg/ml (13.4 μm), respectively. Additionally, GLA‐induced apoptosis and cycle arrest of BIU‐87 and EJ cells in G2 phase. Furthermore, wound healing experiments showed that GLA significantly reduced the migration activities of BIU‐87 and EJ cells. Mechanically, GLA obviously increased the expression of BIM, BAK1, and CYCS in both mRNA and protein levels, which led to the activation of the endogenous apoptotic pathway. Finally, GLA remarkably inhibited the growth of UBC tumors in vivo. In summary, GLA inhibited UBC cells growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest, highlighting that GLA could be utilized as a component to design a novel anti‐UBC drug. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma

Author

Lv, Huijuan, primary, Fei, Yue, additional, Li, Wei, additional, Wang, Yi, additional, Wang, Jinni, additional, He, Jin, additional, Liu, Xianming, additional, Li, Lanfang, additional, Qiu, Lihua, additional, Qian, Zhengzi, additional, Zhou, Shiyong, additional, Meng, Bin, additional, Zhai, Qiongli, additional, Ren, Xiubao, additional, Zou, Dehui, additional, Cai, Qingqing, additional, Wang, Xianhuo, additional, and Zhang, Huilai, additional

Published
2022
Full Text
View/download PDF

23. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma

Author

Yi, Shuhua, primary, Yan, Yuting, additional, Jin, Meiling, additional, Bhattacharya, Supriyo, additional, Wang, Yi, additional, Wu, Yiming, additional, Yang, Lu, additional, Gine, Eva, additional, Clot, Guillem, additional, Chen, Lu, additional, Yu, Ying, additional, Zou, Dehui, additional, Wang, Jun, additional, Phan, An T., additional, Cui, Rui, additional, Li, Fei, additional, Sun, Qi, additional, Zhai, Qiongli, additional, Wang, Tingyu, additional, Yu, Zhen, additional, Liu, Lanting, additional, Liu, Wei, additional, Lyv, Rui, additional, Sui, Weiwei, additional, Huang, Wenyang, additional, Xiong, Wenjie, additional, Wang, Huijun, additional, Li, Chengwen, additional, Xiao, Zhijian, additional, Hao, Mu, additional, Wang, Jianxiang, additional, Cheng, Tao, additional, Bea, Silvia, additional, Herrera, Alex F., additional, Danilov, Alexey, additional, Campo, Elias, additional, Ngo, Vu N., additional, Qiu, Lugui, additional, and Wang, Lili, additional

Published
2022
Full Text
View/download PDF

25. Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

Author

Wang, Xianhuo, primary, Fei, Yue, additional, Liu, Xia, additional, Zhang, Tingting, additional, Li, Wei, additional, Jia, Xiaohui, additional, Liu, Xianming, additional, Qiu, Lihua, additional, Qian, Zhengzi, additional, Zhou, Shiyong, additional, Ren, Xiubao, additional, Zhai, Qiongli, additional, Meng, Bin, additional, Li, Lanfang, additional, and Zhang, Huilai, additional

Published
2021
Full Text
View/download PDF

26. Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma

Author

Qian, Zhengzi, primary, Chen, Leiyuan, additional, Wang, Xinyuan, additional, Kan, Yutian, additional, Wang, Yafei, additional, Yu, Yong, additional, Wang, Xiaofang, additional, Zhao, Zhigang, additional, Yang, Hongliang, additional, Ge, Peng, additional, Ding, Tingting, additional, Zhai, Qiongli, additional, and Zhao, Haifeng, additional

Published
2021
Full Text
View/download PDF

28. SET-NUP214 Fusion Gene Involved Early T-Cell Precursor Acute Lymphoblastic Leukemia in Adult with B Marker Expression

Author

Xu,Xiaoying, Zhai,Qiongli, Jin,Hao, Yu,Yong, Han,Dongmei, Zhang,Huilai, Fu,Kai, and Meng,Bin

Subjects
International Journal of General Medicine
Abstract

Xiaoying Xu,1 Qiongli Zhai,1 Hao Jin,2 Yong Yu,3 Dongmei Han,2 Huilai Zhang,4 Kai Fu,5 Bin Meng1 1Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of China; 2International Personalized Cancer Center, Tianjin Cancer Hospital Airport Hospital, Tianjin, People’s Republic of China; 3Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China; 4Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China; 5Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USACorrespondence: Bin MengDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of ChinaTel +86-18622221609Fax +86-22-23340123-6202Email mbincn@163.comKai FuDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USATel +1-716-8451300-4219Email Kai.fu@roswellpark.orgAbstract: Early T-cell precursor acutelymphoblastic leukemia (ETP-ALL) is rare and associated with poor clinical outcome especially in adults. ETP tumor cells that express cross-lineage antigens or lack pan T markers usually pose big challenges to diagnosis, and their prognostic implications are therefore more uncertain. This study reports the unique case of a 44-year-old woman with breast mass as the initial presentation of acute leukemia possessing both T- and B-cell features (cytoplasmic CD3+CD7+CD19+CD79a+). Despite the presence of gene rearrangements of IGH and IGK probably in a small amount of B cells, the patient was diagnosed with T-ALL mainly according to WHO criteria, and further ETP-ALL rather than mixed phenotype ALL based on additional positive expression of stem/myeloid lineage antigens (CD34+CD13+CD33+HLA-DR+). Moreover, in spite of normal karyotype, SET-NUP214 gene fusion is identified, which has not been described in ETP-ALL with bi-phenotype. After intensive chemotherapy, the patient achieved short-term morphologic complete remission but relapsed within one month. This report may expand immunophenotype and clinical behavior of ETP-ALL in adults. Comprehensive evaluations are emphasized in making a differential diagnosis and distinguishing subtypes of acute leukemia.Keywords: adult acute lymphoblastic leukemia, early T-cell precursor, mixed phenotype acute leukemia, breast infiltration, SET-NUP214 fusion gene

Published
2021

29. Targeting of CD44 eradicates human acute myeloid leukemic stem cells

Author

Jin, Liqing, Hope, Kristin J, Zhai, Qiongli, Smadja-Joffe, Florence, and Dick, John E

Abstract

The long-term survival of patients with acute myeloid leukemia (AML) is dismally poor. A permanent cure of AML requires elimination of leukemic stem cells (LSCs), the only cell type capable of initiating and maintaining the leukemic clonal hierarchy. We report a therapeutic approach using an activating monoclonal antibody directed to the adhesion molecule CD44. In vivo administration of this antibody to nonobese diabetic-severe combined immune-deficient mice transplanted with human AML markedly reduced leukemic repopulation. Absence of leukemia in serially transplanted mice demonstrated that AML LSCs are directly targeted. Mechanisms underlying this eradication included interference with transport to stem cell-supportive microenvironmental niches and alteration of AML-LSC fate, identifying CD44 as a key regulator of AML LSCs. The finding that AML LSCs require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML LSCs and may be applicable to other types of cancer stem cells., Author(s): Liqing Jin [1, 3]; Kristin J Hope [1, 3]; Qiongli Zhai [2]; Florence Smadja-Joffe [2]; John E Dick (corresponding author) [1] AML is a heterogeneous clonal disorder marked by [...]

Published
2006
Full Text
View/download PDF

30. Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma”

Author

Zhang, Tingting, primary, Ren, Tianyuan, additional, Song, Zheng, additional, Zhao, Jing, additional, Jiao, Lei, additional, Zhang, Zhenzhen, additional, He, Jin, additional, Liu, Xianming, additional, Qiu, Lihua, additional, Li, Lanfang, additional, Zhou, Shiyong, additional, Meng, Bin, additional, Zhai, Qiongli, additional, Ren, Xiubao, additional, Qian, Zhengzi, additional, Wang, Xianhuo, additional, and Zhang, Huilai, additional

Published
2021
Full Text
View/download PDF

31. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma

Author

Zhang, Tingting, primary, Ren, Tianyuan, additional, Song, Zheng, additional, Zhao, Jing, additional, Jiao, Lei, additional, Zhang, Zhenzhen, additional, He, Jin, additional, Liu, Xianming, additional, Qiu, Lihua, additional, Li, Lanfang, additional, Zhou, Shiyong, additional, Meng, Bin, additional, Zhai, Qiongli, additional, Ren, Xiubao, additional, Qian, Zhengzi, additional, Wang, Xianhuo, additional, and Zhang, Huilai, additional

Published
2020
Full Text
View/download PDF

32. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study

Author

Yu, Li, primary, Shi, Menghan, additional, Cai, Qingqing, additional, Strati, Paolo, additional, Hagemeister, Fredrick, additional, Zhai, Qiongli, additional, Li, Ling, additional, Fang, Xiaosheng, additional, Li, Jianyong, additional, Sun, Ruifang, additional, Zhang, Shanxiang, additional, Yang, Hanjin, additional, Wang, Zhaoming, additional, Qian, Wenbin, additional, Iwaki, Noriko, additional, Sato, Yasuharu, additional, Zhang, Lu, additional, Li, Jian, additional, Oksenhendler, Eric, additional, Xu-Monette, Zijun Y., additional, and Young, Ken H., additional

Published
2020
Full Text
View/download PDF

33. Overexpression of microRNA‑130a predicts adverse prognosis of primary gastrointestinal diffuse large B‑cell lymphoma

Author

Chen, Leiyuan, primary, Kan, Yutian, additional, Wang, Xinyuan, additional, Ge, Peng, additional, Ding, Tingting, additional, Zhai, Qiongli, additional, Wang, Yafei, additional, Yu, Yong, additional, Wang, Xiaofang, additional, Zhao, Zhigang, additional, Yang, Hongliang, additional, Liu, Xianming, additional, Li, Lanfang, additional, Qiu, Lihua, additional, Zhang, Huilai, additional, Qian, Zhengzi, additional, and Zhao, Haifeng, additional

Published
2020
Full Text
View/download PDF

34. miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma

Author

Wang, Xinyuan, primary, Kan, Yutian, additional, Chen, Leiyuan, additional, Ge, Peng, additional, Ding, Tingting, additional, Zhai, Qiongli, additional, Yu, Yong, additional, Wang, Xiaofang, additional, Zhao, Zhigang, additional, Yang, Hongliang, additional, Liu, Xianming, additional, Li, Lanfang, additional, Qiu, Lihua, additional, Qian, Zhengzi, additional, Zhang, Huilai, additional, Wang, Yafei, additional, and Zhao, Haifeng, additional

Published
2020
Full Text
View/download PDF

35. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Lin, Guo-Wang, primary, Xu, Caigang, additional, Chen, Kexin, additional, Huang, Hui-Qiang, additional, Chen, Jieping, additional, Song, Bao, additional, Chan, John K C, additional, Li, Wenyu, additional, Liu, Weiping, additional, Shih, Lee-Yung, additional, Chuang, Wen-Yu, additional, Kim, Won Seog, additional, Tan, Wen, additional, Peng, Rou-Jun, additional, Laurensia, Yurike, additional, Cheah, Daryl Ming Zhe, additional, Huang, DaChuan, additional, Cheng, Chee Leong, additional, Su, Yi-Jiun, additional, Tan, Soo-Yong, additional, Ng, Siok-Bian, additional, Tang, Tiffany Pooi Ling, additional, Han, Kyudong, additional, Wang, Vivien Ya-Fan, additional, Jia, Wei-Hua, additional, Pei, Zhong, additional, Li, Ya-Jun, additional, Gao, Song, additional, Shi, Yongyong, additional, Hu, Zhibin, additional, Zhang, Furen, additional, Zhang, Ben, additional, Zeng, Yi-Xin, additional, Shen, Hongbing, additional, He, Lin, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, Chanock, Stephen, additional, Kwong, Yok-Lam, additional, Lin, Dongxin, additional, Rothman, Nathaniel, additional, Khor, Chiea Chuen, additional, Lan, Qing, additional, Bei, Jin-Xin, additional, Au, Wing-Yan, additional, Chiu, Brian, additional, Fan, Lei, additional, Li, Zheng, additional, LAM, Tai Hing, additional, Liang, Raymond, additional, Yeh, Su-Peng, additional, Xu, Jun, additional, Ip, Dennis Kai Ming, additional, Li, Gandi, additional, Xu, Gang, additional, Wang, Xiaodong, additional, Bai, Ou, additional, Cai, Qing-Qing, additional, Xia, Yi, additional, Chen, Jie-Rong, additional, Luo, Chun-Ling, additional, Xiong, Xiang-Yu, additional, Zeng, Yanni, additional, Wei, Pan-Pan, additional, Liu, Chu-Jun, additional, Liu, Yu-Xiang, additional, Cao, Yu-Lu, additional, He, Shuai, additional, Liu, Yang, additional, Ha, Jeslin Chian Hung, additional, Khoo, Lay Poh, additional, Kee, Rebecca Xiangpin, additional, Tan, Jing, additional, Liu, Yanhui, additional, Zhang, Fen, additional, Feng, Yanfen, additional, Rao, Huilan, additional, Chng, Wee Joo, additional, Chan, Jason Yong Sheng, additional, Somasundaram, Nagavalli D/O, additional, Tao, Miriam, additional, Ras, Mohamad Farid Bin Harunal, additional, Yeoh, Kheng-Wei, additional, Goh, Yeow Tee, additional, Ong, Shin Yeu, additional, Grigoropoulos, Nicholas Francis, additional, Wong, Esther Kam Yin, additional, Pang, Jane Wan Lu, additional, Lim, Jing Quan, additional, Chia, Burton Kuan Hui, additional, Kim, Seok Jin, additional, Yoon, Sang Eun, additional, Choi, Seungkyu, additional, Kuo, Ching-Yuan, additional, Chen, Tsai-Yun, additional, Su, Yu-Chieh, additional, Huang, Wen-Tsung, additional, Lee, Ming-Yang, additional, Yao, Wenxiu, additional, Ngan, Kai-Cheong, additional, Liu, Herman, additional, Lee, Harold, additional, Yip, Sze-Fai, additional, Liu, Jie, additional, Li, Jianyong, additional, Rabkin, Charles S., additional, Berndt, Sonja, additional, Bassig, Bryan, additional, Hu, Wei, additional, Zhao, Mingfeng, additional, Li, Yuming, additional, Zhai, Qiongli, additional, Shao, Zonghong, additional, Qiu, Lugui, additional, Wang, Jianxiang, additional, Xu, Fu-Ping, additional, Chen, Ling, additional, Hou, Yu, additional, Xu, Shuangnian, additional, Huang, Zhen, additional, Xie, Mingling, additional, Li, Ming, additional, Zhong, Shilong, additional, Zhang, Yan, additional, Gu, Dongqing, additional, Wang, Xin, additional, Foo, Jia Nee, additional, Li, Zhiqiang, additional, Dai, Juncheng, additional, Sun, Liangdan, additional, Wang, Zhenzhen, additional, Liu, Hong, additional, Zhou, Hui, additional, Sun, Yonghu, additional, Koh, Woon-Puay, additional, Heng, Chew-Kiat, additional, Hong, Chew Soo, additional, Ahn, Jeeyun, additional, Park, Kyu Hyung, additional, Tin, Aung, additional, Gu, Jieruo, additional, Xia, Xiaojun, additional, Li, Bo, additional, and Yu, Xueqing, additional

Published
2020
Full Text
View/download PDF

38. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T‑cell lymphoma

Author

Zhang, Huilai, primary, Lv, Huijuan, additional, Jia, Xiaohui, additional, Hu, Ge, additional, Kong, Lingzhe, additional, Zhang, Tingting, additional, Li, Linyu, additional, Pan, Yi, additional, Zhai, Qiongli, additional, Meng, Bin, additional, Wang, Xi, additional, Wang, Huaqing, additional, and Wang, Xianhuo, additional

Published
2019
Full Text
View/download PDF

40. Tumor CD73/A2aR adenosine immunosuppressive axis and tumor‐infiltrating lymphocytes in diffuse large B‐cell lymphoma: correlations with clinicopathological characteristics and clinical outcome

Author

Wang, Xianhuo, primary, Zhang, Tingting, additional, Song, Zheng, additional, Li, Linyu, additional, Zhang, Xuhan, additional, Liu, Jing, additional, Liu, Xianming, additional, Qiu, Lihua, additional, Qian, Zhengzi, additional, Zhou, Shiyong, additional, Feng, Lixia, additional, Hu, Ge, additional, Meng, Bin, additional, Zhai, Qiongli, additional, Ren, Xiubao, additional, Fu, Kai, additional, Li, Lanfang, additional, Wang, Ping, additional, and Zhang, Huilai, additional

Published
2019
Full Text
View/download PDF

41. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma.

Author

Zhang, Tingting, Ren, Tianyuan, Song, Zheng, Zhao, Jing, Jiao, Lei, Zhang, Zhenzhen, He, Jin, Liu, Xianming, Qiu, Lihua, Li, Lanfang, Zhou, Shiyong, Meng, Bin, Zhai, Qiongli, Ren, Xiubao, Qian, Zhengzi, Wang, Xianhuo, and Zhang, Huilai

Subjects
T cells, B cells, LIGANDS (Biochemistry), SURVIVAL analysis (Biometry), LYMPHOMAS
Abstract

Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies. However, there remains a considerable lack of data on Tim-3 signalling, especially the genetic characteristics and immune microenvironment, in diffuse large B cell lymphoma (DLBCL). Herein, we identified three genetic mutations in galectin-9, a major ligand of Tim-3, in six patients with DLBCL (6/188, 3.2%) that were not detected in the COSMIC database. The Oncomine database showed that the mRNA levels of Tim-3 were higher in DLBCL cells than those in normal B cells. Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3+ TILs) exhibited poor outcomes than those with Tim-3- TILs (p = 0.041). The median survival times of these patients were 65.0 (95% confidence interval (CI): 71.2-88.6) and 79.9 months (95% CI: 54.4-75.6), respectively. Furthermore, we defined a novel subtype of exhausted T cells, named as exhausted Tim-3+ CD8+ T cells, and found that patients with exhausted Tim-3+ CD8+ T cells (median survival, 62.8 months, 95% CI: 50.0-75.6) exhibited shorter survival than those with nonexhausted Tim-3- CD8+ T cells (median survival, 82.5 months, 95% CI: 72.0-92.9; p = 0.034). Overall, these findings provide the genetic status of the Tim-3 ligand in DLBCL. Patients with Tim-3+ TILs and exhausted Tim-3+ CD8+ T cells exhibited inferior survival, thus highlighting the possibility of potential therapeutic applications of the inhibition of Tim-3 alone or in combination with other immune checkpoints for treatment of patients with DLBCL. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.

Author

Wu, Jianghua, Zhang, Yanhui, Ding, Tingting, Cheng, Runfen, Gong, Wenchen, Guo, Yuhong, Luo, Ye, Pan, Yi, Zhai, Qiongli, Sun, Wei, Lin, Dongmei, and Sun, Baocun

Abstract

Napsin A is widely used in the diagnosis of lung adenocarcinoma and has also been reported to be positive in cases of thyroid carcinomas. We investigated napsin A levels through immunohistochemistry on whole sections of 210 primary thyroid tumors of various subtypes and another 41 metastatic thyroid carcinomas, and compared these with 125 primary and 25 metastatic lung adenocarcinomas. The results showed that napsin A was expressed in 23.8% thyroid tumors and 30.3% papillary thyroid carcinomas. Most cases showed a focal and weak to moderate expression. In comparison, 80.8% primary lung adenocarcinomas expressed napsin A, with mostly diffused and strong expression. For metastatic carcinomas of thyroid and lung origin, napsin A was detected in 39.0% of thyroid carcinomas in contrast to 88.0% in cases of lung adenocarcinomas. Comparisons of additional markers, TTF-1, CK7, thyroglobulin, and Pax-8 in metastatic carcinomas showed the overlapping expression of immunomarkers of TTF-1 and CK7. Thyroglobulin and Pax-8 were useful for distinguishing between metastatic carcinomas; however, Pax-8 may be a superior marker due to its higher sensitivity. The clinicopathological analysis of papillary thyroid carcinomas showed that the expression of napsin A was positively correlated with lymph node metastasis (p = 0.030). Here, we focused on the expression of napsin A in thyroid tumors and compared it with that in lung adenocarcinomas. The expression of napsin A is common in thyroid tumors and the combined expression of napsin A and TTF-1 in a metastatic thyroid carcinoma is a cause for concern due to chances of misdiagnosis as lung adenocarcinoma. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors

Author

Cao, Yang, primary, Zhu, Tao, additional, Zhang, Peiling, additional, Xiao, Min, additional, Yi, Shuhua, additional, Yang, Yan, additional, Li, Qinlu, additional, Ling, Shaoping, additional, Wang, Yafei, additional, Gao, Lili, additional, Zhu, Li, additional, Wang, Jue, additional, Wang, Na, additional, Huang, Liang, additional, Zhang, Peihong, additional, Zhai, Qiongli, additional, Qiu, Lugui, additional, and Zhou, Jianfeng, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results